Influence of the combination of SGLT2 inhibitors and GLP-1 receptor agonists on eGFR decline in type 2 diabetes: post-hoc analysis of RECAP study.

MLA

Muta, Yoshimi, et al. “Influence of the Combination of SGLT2 Inhibitors and GLP-1 Receptor Agonists on EGFR Decline in Type 2 Diabetes: Post-Hoc Analysis of RECAP Study.” Frontiers in Pharmacology, vol. 15, Mar. 2024, p. 1358573. EBSCOhost, https://doi.org/10.3389/fphar.2024.1358573.

APA

Muta, Y., Kobayashi, K., Toyoda, M., Tone, A., Suzuki, D., Tsuriya, D., Machimura, H., Shimura, H., Takeda, H., Yokomizo, H., Takeshita, K., Chin, K., Kanasaki, K., Tamura, K., Miyauchi, M., Saburi, M., Morita, M., Yomota, M., Kimura, M., … Kawanami, D. (2024). Influence of the combination of SGLT2 inhibitors and GLP-1 receptor agonists on eGFR decline in type 2 diabetes: post-hoc analysis of RECAP study. Frontiers in Pharmacology, 15, 1358573. https://doi.org/10.3389/fphar.2024.1358573

Chicago

Muta, Yoshimi, Kazuo Kobayashi, Masao Toyoda, Atsuhito Tone, Daisuke Suzuki, Daisuke Tsuriya, Hideo Machimura, et al. 2024. “Influence of the Combination of SGLT2 Inhibitors and GLP-1 Receptor Agonists on EGFR Decline in Type 2 Diabetes: Post-Hoc Analysis of RECAP Study.” Frontiers in Pharmacology 15 (March): 1358573. doi:10.3389/fphar.2024.1358573.